|
D-MPH in the treatment of fatigue and neurobehavioral function related to chemotherapy in adult cancer patients Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on D-MPH in the treatment of fatigue and neurobehavioral function related to chemotherapy in adult cancer patients conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. D-MPH in the treatment of fatigue and neurobehavioral function related to chemotherapy in adult cancer patients Clinical research trials and D-MPH in the treatment of fatigue and neurobehavioral function related to chemotherapy in adult cancer patients healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including D-MPH in the treatment of fatigue and neurobehavioral function related to chemotherapy in adult cancer patients. D-MPH in the treatment of fatigue and neurobehavioral function related to chemotherapy in adult cancer patients Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a D-MPH in the treatment of fatigue and neurobehavioral function related to chemotherapy in adult cancer patients clinical trial. Test subjects typically receive the most effective healthcare possible for their D-MPH in the treatment of fatigue and neurobehavioral function related to chemotherapy in adult cancer patients condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "D" Clinical Trials Conditions > D-MPH in the treatment of fatigue and neurobehavioral function related to chemotherapy in adult cancer patients  D-MPH in the treatment of fatigue and neurobehavioral function related to chemotherapy in adult cancer patients
D-MPH in the treatment of fatigue and neurobehavioral function related to chemotherapy in adult cancer patients
For Condition: Fatigue,Neoplasms
Status: Completed
Sponsor(s): Celgene Corporation ,
Synopsis: To evaluate the efficacy of dexmethylphenidate (d-MPH) in the treatment of chemotherapy-related fatigue in adult cancer subjects.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/70 Years
Genders: Both
Protocol Entry Criteria: - Diagnosis of cancer, excluding primary or metastatic brain tumors. - Treated with a minimum of four cycles of a cytotoxic chemotherapy, the last chemotherapy treatment must have been completed at least 2 months prior to study entry. - Physical/neurological examination consistent with the absence of a focal neurological deficit - Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test. In addition, sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner). - Subjects must be able to adhere to the protocol requirements. - Subjects must understand and voluntarily sign an informed consent document. - Subjects must be a native English speaker or fluent in English, and have at least an eighth grade education.
Total Enrollment: 160
Location and Contact Information:
Northwest Medical Specialists, PLLC
Tacoma, Washington, 98405
United States
University of Alabama Palliative Care Institute
Birmingham, Alabama, 35294-0023
United States
Cooper Green Hospital, Jefferson Clinic
Birmingham, Alabama, 35233
United States
Gynecologic Oncology Associates and Development LLC
Greenville, South Carolina, 29604
United States
Beth Israel Cancer Center
New York City, New York, 10003
United States
Markey Cancer Center
Lexington, Kentucky, 40536
United States
Sinai Hospital of Baltimore
Baltimore, Maryland, 21215
United States
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33162
United States
Peak Performance Wellness
Flagstaff, Arizona, 86004
United States
California Cancer Care Inc
Greenbrae, California, 94904-2007
United States
UW Comprehensive Cancer Center
Madison, Wisconsin, 53792-6164
United States
Comprehensive Cancer Centers of the Desert
Palm Springs, California, 92262
United States
Cancer Research Network Inc
Plantation, Florida, 33324
United States
Osler Clinical Research/Osler Medical Inc
Melbourne, Florida, 32901
United States
Piedmont Hospital
Atlanta, Georgia, 30309
United States
Clinical Trials and Research Associates
Montebello, California, 90640
United States
Alta Bates Comprehensive Cancer Center
Berkeley, California, 94704
United States
Arizona Clinical Research Center
Tucson, Arizona, 85712
United States
University of Miami, Sylvester Cancer Research Center
Miami, Florida, 33139
United States
Comprehensive Cancer Center
Boca Raton, Florida, 33428
United States
Seattle Cancer Care Alliance
Seattle, Washington, 98109-1023
United States
Additional Information:
Study ID Numbers: d-MPH-COG-002;
Study Start Date: June 2002
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00047476
Other Fatigue Studies:
1. A Pharmacokinetic Study of Valacyclovir in Pediatric Oncology Patients
2. Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination with Gemcitabine and Cisplatin in Advanced Cancer
3. Constipation in Pediatric Cancer Patients Receiving Vinca Alkaloids or Narcotics
4. Treatment of neutropenic patients with fever who are suspected to have a gram positive infection (a specific kind of bacteria)
5. Dosing and Safety Study of E7820 in Patients with a Malignant Solid Tumor or Lymphoma
Related Studies:
Other Fatigue Clinical Trials
Other Florida Clinical Trials
Other Melbourne Clinical Trials
D-MPH in the treatment of fatigue and neurobehavioral function related to chemotherapy in adult cancer patients
|
|
|
|
|
|
|
|
